Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE SR versus BRONITIN MIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE SR versus BRONITIN MIST.
AEROLATE SR vs BRONITIN MIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (cAMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
BRONITIN MIST contains isoproterenol, a non-selective beta-adrenergic agonist that stimulates beta-1 and beta-2 receptors, leading to bronchodilation via relaxation of bronchial smooth muscle, increased heart rate, and increased contractility.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
For acute bronchospasm: 1-2 inhalations (0.1 mg per inhalation) via aerosol inhaler every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in hepatic or renal impairment, requiring dose adjustment.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Primarily renal (approximately 70-80% as unchanged drug and metabolites); biliary/fecal excretion accounts for 20-30%.
Category C
Category C
Bronchodilator
Bronchodilator